CMO Messaging - Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals

MHRA Central Alerting System team Coronavirus alerts banner

CMO Messaging - Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals

Dexamethasone has been demonstrated to have a clear place in the management of hospitalised patients with COVID-19. There were no excess harms identified in using this dose of dexamethasone in this patient population. Dexamethasone was not used in pregnant women.

Clinicians should therefore consider dexamethasone for the management of hospitalised patients with COVID-19 who require oxygen or ventilation.

Out of hospital treatment is not appropriate.

There is no current or anticipated constraint on supply of the medicine in the UK.

Access the alert here

Thank you,
Central Alerting System team, MHRA

If you would like to share this with a friend or colleague, hit the Forward button or send them this link to view the email in a browser.

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to safetyalerts@subscriptions.mhra.gov.uk

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.